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A 82 years old patient was admitted for persisting abnormalities of iron metabolism 
parameters in the context IgG kappa monoclonal gammopathy, discovered 12 years before, 
and classified as MGUS (monoclonal gammopathy of undetermined significance). Serum iron 
and transferrin concentration were constantly extremely high (96.9 µmol/L and 5.0 g/L, 
respectively), transferrin saturation was elevated (77.5% ; N<45%) and serum ferritin 
moderately increased (608µg/L ; N<300 µg/L). Hemochromatosis was ruled out
(1)
 : no tissue 
iron overload was present and genetic studies searching for mutations in HFE and non HFE 
genes, were negative (p.Cys282Tyr mutation, HJV (HFE2), HAMP, TFR2, BMP6, SLC40A1 and 
FTL). The diagnosis of monoclonal antitransferrin antibody was therefore highly suspected. A 
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more in depth study of iron metabolism was performed to get a better understanding of the 
disease.  
According to Alyanakian et al
(2)
, we observed (Fig. 1A) Tf in the serum and in the IgG eluate 
fraction after affinity precipitation, confirming the presence of IgG directed against 
transferrin. Furthermore, the addition of purified transferrin in the serum prior to 
immunoglobulin affinity purification increased the amount of purified immunoglobulin 
transferrin complexes, suggesting the presence, in the serum, of unbound anti-transferrin 
IgG. To further characterize transferrin, its sialylation was studied. The basic electrophoretic 
profile (Fig.2B) did not provide interpretable information. However, after 
immunoprecipitation of transferrin-IgG complexes, the remaining free transferrin glycoforms 
were, as expected, clearly found (Fig. 2C).  The very high levels of serum iron and transferrin 
concentration suggest that the transferrin-IgG interaction could modify the ability of 
transferrin to link iron. Therefore, the increased transferrin concentration could be a 
compensatory mechanism aiming to maintain a normal affinity of the immunoglobulin-free 
transferrin for iron. Little is known on the mechanisms which determine transferrin 
synthesis, in contrast with the molecular regulation of transferrin receptor 1 synthesis. It 
could be proposed that the IgG-transferrin complex generates a form of acquired functional 
hypotransferrinemia triggering, in turn, transferrin oversynthesis by the hepatocytes. 
Another mechanism could be the development of an iron-deficiency like status. Indeed, in 
agreement with Forni et al who found decreased urinary or serum hepcidin levels in 2 of 
their 3 patients
(3)
, the hepcidin/ferritin ratio was strongly decreased (<0.1–N: 4-30). These 
results closely remind the HFE genetic hemochromatosis profile, a condition related to a 
decoupling between iron status (including transferrin saturation) and hepcidin expression
(4)
.  
In the case of circulating anti-transferrin monoclonal antibody, a disturbed interaction 
between transferrin iron and transferrin receptor 1 could impede iron delivery to cells, thus 
creating cellular iron deprivation, a condition leading an increase of transferrin synthesis. 
We, therefore, explored whether the transferrin-IgG interaction disturbed the stability of the 
transferrin-iron complex. This was approached by quantifying abnormal forms of iron in 
serum.  On the one hand, normal NTBI (non-transferrin bound iron)
(5)
 concentration 
(<0.5µmol/L), despite high transferrin saturation, suggested that the serum transferrin 
increase ensured the control of all the iron present in the serum. On the other hand, high LPI 
(labile plasma iron)
(6)
 concentration (0.92µmol/L – N<0.5µmol/L) despite normal NTBI, 
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suggested that unstable iron species, that can be engaged in oxidative stress, was present in 
the serum. This could be related to a weakened interaction between iron and transferrin, 
favored by transferrin-IgG interaction. This observation provides strong support to the fact 
that NTBI and LPI do not cover similar biochemical forms of iron. In this patient, no evidence 
of visceral iron overload or iron-related toxicity was observed. It should be noted that iron 
overload is inconstant in this syndrome.  
In conclusion, the observed abnormalities of iron metabolism in this further case of 
anti-transferrin monoclonal antibody raise important questions on the way this type of 
monoclonal immunoglobulin impacts iron status, especially in altering transferrin-iron 
delivery to cells and in favoring the production of reactive plasma iron. 
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Figure legend 
 
Figure 1: Characterisation of the transferrin / anti-transferrin immunoglobulins 
complex in the patient serum. 
 
Patient serum was first analyzed by western blot (A) prior or after affinity chromatography 
for immunoglobulin IgG  (control sera were used for comparison) and secondly analyzed by 
capillary zone electrophoresis system before (B) and after (C) immunoprecipitation with 
specific anti- IgG, IgA, and IgM in order to determined transferrin glycoform pattern. (see 
methods in supplemental data) 
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